ALYATEC is pleased and proud to announce the finalisation of a clinical study conducted for the American company Regeneron Pharmaceuticals.
The main purpose of this phase 2 study, started in February 2019 and ended in May 2020, was to evaluate the efficacy of a drug candidate based on a combination of monoclonal antibodies to reduce asthmatic symptoms in cat-allergic patients.
56 patients were enrolled and exposed to cat allergen in the new generation environmental exposure chamber of ALYATEC.
The results will be shared by Regeneron Pharmaceuticals shortly and we will communicate about them afterwards through our different communication platforms.
For more information about the study, feel free to visit https://clinicaltrials.gov/ct2/show/NCT03838731.
